159 related articles for article (PubMed ID: 37025409)
1. Incorporation size of lymph node metastasis focus and pre-ablation stimulated Tg could more effectively predict clinical outcomes in differentiated thyroid cancer patients without distant metastases.
Xie J; Chen P; Wang J; Luo X; Luo J; Xiong X; Li C; Pan L; Wu J; Feng H; Ouyang W
Front Endocrinol (Lausanne); 2023; 14():1094339. PubMed ID: 37025409
[TBL] [Abstract][Full Text] [Related]
2. Prognostic Implications of Preablation Stimulated Tg: A Retrospective Analysis of 2500 Thyroid Cancer Patients.
Tian T; Xu Y; Zhang X; Liu B
J Clin Endocrinol Metab; 2021 Oct; 106(11):e4688-e4697. PubMed ID: 34143886
[TBL] [Abstract][Full Text] [Related]
3. The Value of Stimulated Thyroglobulin Before the First Radioactive Iodine Treatment in Metastasis for Differentiated Thyroid Carcinoma.
Ren L; Zhang C; Shen Y; Mo A; Hu Y; Sun J; Yuan C; Wen W
Clin Lab; 2021 Jun; 67(6):. PubMed ID: 34107643
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of serial serum thyroglobulin determinations after total thyroidectomy for differentiated thyroid cancer.
Lima N; Cavaliere H; Tomimori E; Knobel M; Medeiros-Neto G
J Endocrinol Invest; 2002 Feb; 25(2):110-5. PubMed ID: 11929080
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of post-ablation stimulated thyroglobulin in differentiated thyroid cancer patients with biochemical incomplete response: a bi-center observational study.
Wang Y; Wu J; Jiang L; Zhang X; Liu B
Endocrine; 2022 Apr; 76(1):109-115. PubMed ID: 35094313
[TBL] [Abstract][Full Text] [Related]
6. PRE-ABLATION THYROGLOBULIN AND THYROGLOBULIN TO THYROID-STIMULATING HORMONE RATIO MAY BE ASSOCIATED WITH PULMONARY METASTASES IN CHILDREN WITH DIFFERENTIATED THYROID CANCER.
Livhits MJ; Pasternak JD; Xiong M; Li N; Gosnell JE; Yeh MW; Chiu HK
Endocr Pract; 2016 Nov; 22(11):1259-1266. PubMed ID: 27482611
[TBL] [Abstract][Full Text] [Related]
7. Importance of postoperative stimulated thyroglobulin level at the time of 131I ablation therapy for differentiated thyroid cancer.
Hasbek Z; Turgut B; Kilicli F; Altuntas EE; Yucel B
Asian Pac J Cancer Prev; 2014; 15(6):2523-7. PubMed ID: 24761858
[TBL] [Abstract][Full Text] [Related]
8. Detection of distant metastasis at the time of ablation in children with differentiated thyroid cancer: the value of pre-ablation stimulated thyroglobulin.
Liu L; Huang F; Liu B; Huang R
J Pediatr Endocrinol Metab; 2018 Jul; 31(7):751-756. PubMed ID: 29953410
[TBL] [Abstract][Full Text] [Related]
9. The role of technetium-99m methoxyisobutylisonitrile scintigraphy in the planning of therapy and follow-up of patients with differentiated thyroid carcinoma after surgery.
Rubello D; Mazzarotto R; Casara D
Eur J Nucl Med; 2000 Apr; 27(4):431-40. PubMed ID: 10805117
[TBL] [Abstract][Full Text] [Related]
10. Long-term outcome of differentiated thyroid cancer in children and young adults: risk stratification by ATA criteria and assessment of pre-ablation stimulated thyroglobulin as predictors of disease persistence.
Karapanou O; Tzanela M; Rondogianni P; Dacou-Voutetakis C; Chiotis D; Vlassopoulou B; Vassiliadi D; Kanaka-Gantenbein C; Tsagarakis S
Endocrine; 2020 Dec; 70(3):566-574. PubMed ID: 32533509
[TBL] [Abstract][Full Text] [Related]
11. Postoperative stimulated thyroglobulin level and recurrence risk stratification in differentiated thyroid cancer.
Yang X; Liang J; Li TJ; Yang K; Liang DQ; Yu Z; Lin YS
Chin Med J (Engl); 2015 Apr; 128(8):1058-64. PubMed ID: 25881600
[TBL] [Abstract][Full Text] [Related]
12. The value of diagnostic whole-body scanning and serum thyroglobulin in the presence of elevated serum thyrotropin during follow-up of anti-thyroglobulin antibody-positive patients with differentiated thyroid carcinoma who appeared to be free of disease after total thyroidectomy and radioactive iodine ablation.
Rosario PW; Mineiro Filho AF; Lacerda RX; dos Santos DA; Calsolari MR
Thyroid; 2012 Feb; 22(2):113-6. PubMed ID: 22224815
[TBL] [Abstract][Full Text] [Related]
13. Management of thyroid cancer: United Kingdom National Multidisciplinary Guidelines.
Mitchell AL; Gandhi A; Scott-Coombes D; Perros P
J Laryngol Otol; 2016 May; 130(S2):S150-S160. PubMed ID: 27841128
[TBL] [Abstract][Full Text] [Related]
14. Persistent and recurrent disease in patients with papillary thyroid carcinoma with clinically apparent (cN1), but not extensive, lymph node involvement and without other factors for poor prognosis.
Furtado Mde S; Rosario PW; Calsolari MR
Arch Endocrinol Metab; 2015 Aug; 59(4):285-91. PubMed ID: 26331314
[TBL] [Abstract][Full Text] [Related]
15. Postoperative-stimulated serum thyroglobulin measured at the time of 131I ablation is useful for the prediction of disease status in patients with differentiated thyroid carcinoma.
Lee JI; Chung YJ; Cho BY; Chong S; Seok JW; Park SJ
Surgery; 2013 Jun; 153(6):828-35. PubMed ID: 23489940
[TBL] [Abstract][Full Text] [Related]
16. Differentiated Thyroid Cancer lymph-node relapse. Role of adjuvant radioactive iodine therapy after lymphadenectomy.
Piccardo A; Puntoni M; Bottoni G; Treglia G; Foppiani L; Bertoli M; Catrambone U; Arlandini A; Dib B; Altrinetti V; Massollo M; Bossert I; Cabria M; Bertagna F; Giovanella L
Eur J Nucl Med Mol Imaging; 2017 Jun; 44(6):926-934. PubMed ID: 27966046
[TBL] [Abstract][Full Text] [Related]
17. Re-ablation I-131 activity does not predict treatment success in low- and intermediate-risk patients with differentiated thyroid carcinoma.
Prpic M; Kruljac I; Kust D; Kirigin LS; Jukic T; Dabelic N; Bolanca A; Kusic Z
Endocrine; 2016 Jun; 52(3):602-8. PubMed ID: 26732041
[TBL] [Abstract][Full Text] [Related]
18. Long-term course and predictive factors of elevated serum thyroglobulin and negative diagnostic radioiodine whole body scan in differentiated thyroid cancer.
Alzahrani AS; Mohamed G; Al Shammary A; Aldasouqi S; Abdal Salam S; Shoukri M
J Endocrinol Invest; 2005 Jun; 28(6):540-6. PubMed ID: 16117196
[TBL] [Abstract][Full Text] [Related]
19. Ongoing risk stratification for differentiated thyroid cancer (DTC) - stimulated serum thyroglobulin (Tg) before radioiodine (RAI) ablation, the most potent risk factor of cancer recurrence in M0 patients.
Krajewska J; Jarząb M; Czarniecka A; Roskosz J; Kukulska A; Handkiewicz-Junak D; Puch Z; Wygoda Z; Paliczka-Cieślik E; Kropińska A; Gubała E; Jurecka-Lubieniecka B; Jarząb B
Endokrynol Pol; 2016; 67(1):2-11. PubMed ID: 26884109
[TBL] [Abstract][Full Text] [Related]
20. UNFAVORABLE RESPONSES TO RADIOIODINE THERAPY IN N1B PAPILLARY THYROID CANCER: A PROPENSITY SCORE MATCHING STUDY.
Liu YQ; Li H; Liu JR; Lin YS
Endocr Pract; 2019 Dec; 25(12):1286-1294. PubMed ID: 31412228
[No Abstract] [Full Text] [Related]
[Next] [New Search]
